Pharmaceutical Industry

Notizia

Arming antibiotics with a vaccination-like immune responseHarnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Le...

Allergic Conjunctivitis (AC)- Market Insights, Epidemiology and Market Forecast- 2027

Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including ...

Hepatic Encephalopathy- An ailment of liver to brain

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-st...

NF-κB Inhibitors- A Promising Future

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production...

Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly termin...

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with ...

Parkinson’s and tuberculosis shares a common protein that could provide better drugs for both

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson's disease. The study has identified th...

Business Cocktail

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the ...

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structure...

Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistan...

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After th...